Global Prescription Digital Therapeutics (DTx) Market is rising gradually with a healthy CAGR of 23.35% in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth. Few of the major competitors currently working in the global prescription digital therapeutics (DTx) market are Better Therapeutics, LLC, BigHealth, Headspace Inc, Kaia Health, Xealth, Solera Network, F. Hoffmann-La Roche Ltd, ResMed, Pear Therapeutics, Inc, Omada Health, Inc., WellDoc, Inc, Voluntis, Teva Pharmaceutical Industries Ltd, 2Morrow Inc, SAMSUNG among others.